Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Weger, W.
Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents
Br J Pharmacol. 2010; 160(4):810-820
Doi: 10.1111/j.1476-5381.2010.00702.x
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Weger Wolfgang
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Psoriasis is a chronic inflammatory disease affecting 1-3% of the general population. Among psoriatic patients, 5-40% are affected by psoriatic arthritis. Due to the chronic nature of the disease, patients suffer from substantial psychological and financial burdens, thus adding to a significantly impaired quality of life. Traditional systemic therapies for psoriasis, such as methotrexate, cyclosporin A, retinoids or PUVA therapy, have a potential for long-term toxicity and may not always provide sufficient improvement of the disease. The development of novel therapies targeting key steps in the pathogenesis of psoriasis and psoriatic arthritis now provide new and efficient treatment options. Biological therapies for the treatment of psoriasis and/or psoriatic arthritis are defined by their mode of action and can be classified into three categories: the T-cell modulating agents (alefacept and efalizumab), the inhibitors of tumour necrosis factor-alpha (TNFalpha blockers, e.g. adalimumab, certolizumab, etanercept, golimumab and infliximab) and the inhibitors of interleukin (IL) 12 and IL-23 (e.g. ustekinumab and briakinumab). This article provides a brief overview of the currently approved biological agents in the European Union and of some newer agents, such as briakinumab, certolizumab and golimumab.
- Find related publications in this database (using NLM MeSH Indexing)
- Animals -
- Anti-Inflammatory Agents, Non-Steroidal - adverse effects
- Antibodies, Monoclonal - adverse effects
- Arthritis, Psoriatic - drug therapy
- Biological Agents - adverse effects
- Chronic Disease -
- Humans -
- Immunoglobulin Fragments - adverse effects
- Interleukin-12 - antagonists & inhibitors
- Interleukin-23 - antagonists & inhibitors
- Product Surveillance, Postmarketing -
- Psoriasis - drug therapy
- Recombinant Fusion Proteins - adverse effects
- T-Lymphocytes - drug effects
- Tumor Necrosis Factor-alpha - antagonists & inhibitors
- Find related publications in this database (Keywords)
- briakinumab
- certolizumab
- golimumab
- psoriasis
- psoriatic arthritis
- ustekinumab